These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 12577933)

  • 1. [Molecular physiopathology of viral hepatitis].
    Hayashi N; Kanto T; Hosui A; Sugimoto Y; Okawa K; Takehara T; Sasaki Y
    Nihon Naika Gakkai Zasshi; 2002 Sep; 91 Suppl():89-93. PubMed ID: 12577933
    [No Abstract]   [Full Text] [Related]  

  • 2. Altered innate immunity in chronic hepatitis C infection: cause or effect?
    Szabo G; Chang S; Dolganiuc A
    Hepatology; 2007 Oct; 46(4):1279-90. PubMed ID: 17886338
    [No Abstract]   [Full Text] [Related]  

  • 3. Changes in hepatitis C virus (HCV) antibody status in patients with chronic hepatitis C after eradication of HCV infection by interferon therapy.
    Toyoda H; Kumada T; Kiriyama S; Sone Y; Tanikawa M; Hisanaga Y; Kuzuya T; Honda T; Hayashi K; Nakano I; Katano Y; Goto H
    Clin Infect Dis; 2005 Mar; 40(6):e49-54. PubMed ID: 15736006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Relationship between the dynamics of cytokines and the phenotypes of the disease in chronic HCV infection].
    Okumura A; Kakumu S
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):164-9. PubMed ID: 15359786
    [No Abstract]   [Full Text] [Related]  

  • 5. [Mechanisms and significance of apoptosis suppression by HCV core protein].
    Otsuka M; Kato N; Omata M
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):185-90. PubMed ID: 15359790
    [No Abstract]   [Full Text] [Related]  

  • 6. Dendritic cells in chronic viral hepatitis B and C: victims or guardian angels?
    Woltman AM; Boonstra A; Janssen HL
    Gut; 2010 Jan; 59(1):115-25. PubMed ID: 20007959
    [No Abstract]   [Full Text] [Related]  

  • 7. The molecular basis of HCV-mediated immune dysregulation.
    Eisen-Vandervelde AL; Yao ZQ; Hahn YS
    Clin Immunol; 2004 Apr; 111(1):16-21. PubMed ID: 15093547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C virus E2 and CD81 interaction may be associated with altered trafficking of dendritic cells in chronic hepatitis C.
    Nattermann J; Zimmermann H; Iwan A; von Lilienfeld-Toal M; Leifeld L; Nischalke HD; Langhans B; Sauerbruch T; Spengler U
    Hepatology; 2006 Oct; 44(4):945-54. PubMed ID: 17006905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Symposium on clinical aspects in hepatitis virus infection. 4. Topics of type C chronic liver disease.
    Hayashi N
    Intern Med; 2001 Feb; 40(2):180-1. PubMed ID: 11300162
    [No Abstract]   [Full Text] [Related]  

  • 10. [Topics on type C chronic hepatitis].
    Hayashi N
    Nihon Naika Gakkai Zasshi; 2000 Sep; 89(9):1850-3. PubMed ID: 11051661
    [No Abstract]   [Full Text] [Related]  

  • 11. Quantitative determination of hepatitis C core antigen in therapy monitoring for chronic hepatitis C.
    Moscato GA; Giannelli G; Grandi B; Pieri D; Marsi O; Guarducci I; Batini I; Altomare E; Antonaci S; Capria A; Pellegrini G; Sacco R
    Intervirology; 2011 Feb; 54(2):61-5. PubMed ID: 20829601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Schistosomiasis and antiviral treatment of chronic hepatitis C.
    Di Marco V; Capra M; Gagliardotto F; Ferraro D; Di Stefano R
    Hepatology; 2001 Oct; 34(4 Pt 1):850-1. PubMed ID: 11584389
    [No Abstract]   [Full Text] [Related]  

  • 13. Infection and dysfunction of circulating blood dendritic cells and their subsets in chronic hepatitis C virus infection.
    Tsubouchi E; Akbar SM; Horiike N; Onji M
    J Gastroenterol; 2004 Aug; 39(8):754-62. PubMed ID: 15338369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Interferon therapy in chronic hepatitis C and cellular immunity].
    Nikitin IG; Kuznetsov SL; Mordvinova LN; Uskov IuI; Storozhakov GI; Strochenovskiĭ AB
    Klin Med (Mosk); 1999; 77(6):33-7. PubMed ID: 10459217
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluation of the clinical usefulness of COBAS AMPLICOR HCV MONITOR assay (ver2.0): Comparison with AMPLICOR HCV MONITOR assay (ver1.0) and HCV core protein level.
    Kawai S; Yokosuka O; Imazeki F; Saisho H; Mizuno C
    J Med Virol; 2002 Nov; 68(3):343-51. PubMed ID: 12226820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [HCV core protein effects on the expression of mutation p53 and Bcl-2 protein in HCV hepatitis and cirrhosis].
    Wang WY; Zhang ZP; Huang LJ; Ma FC; Zhao YL
    Zhonghua Gan Zang Bing Za Zhi; 2005 Feb; 13(2):148-9. PubMed ID: 15727713
    [No Abstract]   [Full Text] [Related]  

  • 17. Current and future hepatitis C therapies.
    Firpi RJ; Nelson DR
    Arch Med Res; 2007 Aug; 38(6):678-90. PubMed ID: 17613359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of specific humoral response to hepatitis C core antigen in children].
    Kupś J; Woźniakowska-Gesicka T
    Przegl Lek; 2003; 60(12):802-5. PubMed ID: 15058020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular immunity to hepatitis C virus core protein and the response to interferon in patients with chronic hepatitis C.
    Lasarte JJ; García-Granero M; López A; Casares N; García N; Civeira MP; Borrás-Cuesta F; Prieto J
    Hepatology; 1998 Sep; 28(3):815-22. PubMed ID: 9731578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasmacytoid dendritic cells in acute and chronic hepatitis C virus infection.
    Ulsenheimer A; Gerlach JT; Jung MC; Gruener N; Wächtler M; Backmund M; Santantonio T; Schraut W; Heeg MH; Schirren CA; Zachoval R; Pape GR; Diepolder HM
    Hepatology; 2005 Mar; 41(3):643-51. PubMed ID: 15726647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.